GlassScriptPhysician profile
Jonathan Burhan Imran
NPI 1639513054
$8,159.88
in general payments reported to CMS, 2019-2025
13 companies · $1,569 in 2025
The $1,569 reported for 2025 was more than what 76% of Surgical Critical Care providers received nationally (typical 2025 total: $234).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $36.17 · 2023: $170 · 2024: $6,385 · 2025: $1,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,500 · Education: $2,500 · Food and Beverage: $2,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,500.08 |
| Education | $2,500.00 |
| Food and Beverage | $2,123.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,050.88 | 2023-2025 | Da Vinci Surgical System |
| Abbvie INC. | $2,022.22 | 2024 | |
| Ethicon US, LLC | $304.70 | 2024-2025 | Dermabond, Surgicel Nu-Knit, Surgiflo Hemostatic Matrix |
| Dilon Technologies, INC. | $157.18 | 2025 | Hemoblast Bellows |
| Alexion Pharmaceuticals, INC. | $153.83 | 2022-2024 | Ultomiris |
| Baxter Healthcare | $143.32 | 2024 | Perclot, Floseal, Seprafilm |
| Medtronic, INC. | $81.87 | 2024 | Signia |
| Davol INC. | $55.09 | 2023 | Phasix Mesh |
| Astrazeneca Pharmaceuticals LP | $49.44 | 2024 | Andexxa |
| Smith+Nephew, INC. | $48.42 | 2024 | Stravix |
| Haemonetics Corporation | $40.98 | 2025 | Teg6s Hemostasis System |
| Solventum Corporation | $38.49 | 2025 | Abthera, Prevena, V.A.C. Veraflo Cleanse Choice |
| E.R. Squibb & Sons, L.L.C. | $13.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Imran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.